Sk Bioscience Co., Ltd. (302440)

Overview

SK bioscience Co.,Ltd. is a prominent figure in the biopharmaceutical industry, focusing on the research, development, manufacturing, and international distribution of vaccines and biopharmaceutical products. With its roots in Korea, SK bioscience extends its footprint globally, offering innovative solutions for a variety of infectious diseases, aiming to bolster public health worldwide. Founded in 2018, the company has quickly established itself as a leader in its field, headquartered in Seongnam-si, South Korea.

Products and Services

Skycellflu: A cell-cultured influenza surface antigen vaccine, showcasing SK bioscience's advanced approach to flu vaccine development.

Skycellflu 4-ga Pre-filled Syringe: An extension of the Skycellflu line, this pre-filled syringe format enhances ease of use and accessibility.

Pneumococcal Vaccine: Designed for both adults and infants, this vaccine targets pneumococcal diseases, aiming to reduce the incidence of infections.

Skyzoster: A vaccine dedicated to the prevention of shingles (herpes zoster), demonstrating SK bioscience’s commitment to addressing viral diseases across various age groups.

Sky Baricella: Aimed at preventing chickenpox infection in children, reinforcing the company's focus on pediatric health.

Oral Rotavirus Vaccine: Currently having completed phase 2 clinical trials, this vaccine represents a shift towards oral vaccination methods for combating rotavirus infections.

Cervical Cancer Vaccine: Having also completed phase 2 clinical trials, this product is a testament to SK bioscience’s dedication to cancer prevention strategies.

Rotavirus Vaccine (Phase 3 in Africa): This vaccine is part of an extensive clinical trial in Africa, highlighting the company’s efforts in contributing to global health by addressing critical diseases in vulnerable populations.

Typhoid Conjugate Vaccine: Addressing another significant global health challenge, this vaccine aims to combat typhoid fever with improved immunogenicity.

Corona 19 Vaccine (Phase 1/1-2): In response to the global pandemic, this vaccine effort showcases SK bioscience’s agility in contributing to the fight against COVID-19.

Low-cost Pneumococcal Vaccine: Completing phase 2 clinical trials, this vaccine initiative is geared towards making pneumococcal disease prevention more accessible globally.

Next-Generation Pneumococcal Vaccine (Phase 2 in the US): Currently in phase 2 clinical trial in the United States, this represents the next step in pneumococcal disease prevention, emphasizing the company's innovative drive.